Dentsply International Inc. (NASDAQ:XRAY)‘s stock had its “outperform” rating reiterated by analysts at Robert W. Baird in a research report issued to clients and investors on Tuesday. They presently have a $67.00 price target on the stock, down from their prior price target of $69.00. Robert W. Baird’s price target points to a potential upside of 13.67% from the company’s current price.
Several other equities analysts have also commented on XRAY. JPMorgan Chase & Co. began coverage on shares of Dentsply International in a research report on Thursday, September 22nd. They issued a “neutral” rating and a $65.00 price objective for the company. Bank of America Corp. began coverage on shares of Dentsply International in a research report on Monday, September 12th. They issued a “buy” rating and a $70.00 price objective for the company. Jefferies Group reaffirmed a “buy” rating on shares of Dentsply International in a research report on Wednesday, August 17th. Zacks Investment Research lowered shares of Dentsply International from a “buy” rating to a “hold” rating in a research report on Monday, August 8th. Finally, Barrington Research lowered shares of Dentsply International from an “outperform” rating to a “market perform” rating in a research report on Monday, August 8th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $66.91.
Shares of Dentsply International (NASDAQ:XRAY) opened at 58.94 on Tuesday. The stock has a 50 day moving average of $60.12 and a 200-day moving average of $61.41. Dentsply International has a 52 week low of $53.06 and a 52 week high of $65.83.
Dentsply International (NASDAQ:XRAY) last released its quarterly earnings results on Friday, August 5th. The company reported $0.76 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.70 by $0.06. The business earned $1.02 billion during the quarter, compared to analyst estimates of $1.03 billion. Dentsply International had a net margin of 11.99% and a return on equity of 9.18%. The company’s quarterly revenue was up 46.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.73 earnings per share. On average, analysts expect that Dentsply International will post $2.76 EPS for the current fiscal year.
The company also recently disclosed a dividend, which will be paid on Friday, October 14th. Stockholders of record on Friday, September 30th will be paid a dividend of $0.0775 per share. The ex-dividend date is Wednesday, September 28th. Dentsply International’s payout ratio is 14.49%.
In other news, VP Rainer Berthan sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $61.12, for a total transaction of $305,600.00. Following the sale, the vice president now owns 34,370 shares of the company’s stock, valued at approximately $2,100,694.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Maureen J. Macinnis sold 45,100 shares of the firm’s stock in a transaction that occurred on Thursday, August 25th. The stock was sold at an average price of $60.55, for a total transaction of $2,730,805.00. Following the sale, the senior vice president now directly owns 36,730 shares in the company, valued at approximately $2,224,001.50. The disclosure for this sale can be found here. Insiders own 2.20% of the company’s stock.
Several large investors have recently modified their holdings of XRAY. BlueMountain Capital Management LLC purchased a new stake in shares of Dentsply International during the first quarter worth approximately $953,000. Bank of Montreal Can bought a new stake in Dentsply International during the second quarter worth about $15,419,000. HBK Investments L P bought a new stake in Dentsply International during the first quarter worth about $512,000. Squarepoint Ops LLC boosted its stake in Dentsply International by 131.0% in the first quarter. Squarepoint Ops LLC now owns 35,475 shares of the company’s stock worth $2,186,000 after buying an additional 20,116 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. boosted its stake in Dentsply International by 52.5% in the second quarter. Candriam Luxembourg S.C.A. now owns 212,680 shares of the company’s stock worth $13,195,000 after buying an additional 73,230 shares in the last quarter. 94.58% of the stock is currently owned by institutional investors and hedge funds.
Dentsply International Company Profile
DENTSPLY SIRONA Inc, formerly DENTSPLY International Inc, designs, develops, manufactures and markets a range of consumable dental products for the professional dental market. The Company also manufactures and markets consumable medical device products consisting mainly of urological catheters and certain surgical products.
Receive News & Ratings for Dentsply International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dentsply International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.